NCT05311397View on ClinicalTrials.gov

A Study of A166 in Patients With Advanced Solid Malignant Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 9, 2018

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Breast Cancer
Interventions
DRUG

A166

A166 is an Antibody Drug Conjugate (ADC) targeting HER2 expressing cancer cells.

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

INDUSTRY

NCT05311397 - A Study of A166 in Patients With Advanced Solid Malignant Tumors | Biotech Hunter | Biotech Hunter